Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism-Reference-Cited by-同舟云学术

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism

Published:2008-03 Issue:3 Volume:49 Page:543-549
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Millar John S.,Brousseau Margaret E.,Diffenderfer Margaret R.,Barrett P. Hugh R.,Welty Francine K.,Cohn Jeffrey S.,Wilson Aisha,Wolfe Megan L.,Nartsupha Chorthip,Schaefer Peter M.,Digenio Andres G.,Mancuso James P.,Dolnikowski Gregory G.,Schaefer Ernst J.,Rader Daniel J.

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference24 articles.

1. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in subjects with low HDL cholesterol;Brousseau;N. Engl. J. Med.,2004

2. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion;Brousseau;Arterioscler. Thromb. Vasc. Biol.,2005

3. Effects of torcetrapib, a cholesteryl ester transfer protein inhibitor, on apolipoprotein B100 metabolism;Millar;Arterioscler. Thromb. Vasc. Biol.,2006

4. Radioimmunoassay studies of human apolipoprotein E;Blum;J. Clin. Invest.,1980

5. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans;Gregg;Clin. Chem.,1988

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly;Arteriosclerosis, Thrombosis, and Vascular Biology;2020-03

2. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E;Journal of Lipid Research;2017-06

3. Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation;Current Opinion in Lipidology;2016-10

4. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9;Journal of Lipid Research;2015-11

5. Recent advances in pharmacotherapy for hypertriglyceridemia;Progress in Lipid Research;2014-10